

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Kindstar Globalgene Technology, Inc.
康聖環球基因技術有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 9960)

VOLUNTARY ANNOUNCEMENT INTENTION OF DIRECTOR TO INCREASE SHAREHOLDING IN THE COMPANY

This announcement is made by Kindstar Globalgene Technology, Inc. (the “**Company**”) on a voluntary basis.

The board of directors (the “**Board**”) of the Company was informed by Dr. Huang Shiang (“**Dr. Huang**”) (the Chairman, Chief Executive Officer, Chief Medical Officer and an executive Director of the Company) of his intention to acquire the shares of the Company (the “**Shares**”) from the open market (“**Shareholding Increase**”), subject to compliance with the applicable laws and regulations. According to Dr. Huang, it is expected that the aggregate amount of consideration for the Shareholding Increase would not exceed HK\$5 million. In addition, Dr. Huang indicated that the Shares proposed to be acquired would be held for medium- to long-term investment purposes, and he had no present intention to sell such Shares during the twelve months after the Shareholding Increase.

The Board considers that the proposed Shareholding Increase demonstrates Dr. Huang’s confidence towards the prospect and growth potential of the Company.

As at the date of this announcement, Dr. Huang (through his family trust) and Ms. Guo Gui-Rong, the spouse of Dr. Huang, (through her family trust as well as her direct shareholding interest) are beneficially interested in approximately 11.40% of the total issued share capital of the Company. As at the date of this announcement, by virtue of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong), each of Dr. Huang and Ms. Guo Gui-Rong is interested in or deemed to be interested in 145,363,368 Shares, representing approximately 16.05% of the total issued share capital of the Company.

Shareholders and the potential investors of the Company should note that as at the date of this announcement, Dr. Huang has not proceeded with the proposed Shareholding Increase. The proposed Shareholding Increase will be subject to the market conditions and will be at the absolute discretion of Dr. Huang. Shareholders and the potential investors of the Company are advised to exercise caution when dealing in the Shares.

By order of the Board
Kindstar Globalgene Technology, Inc.
康聖環球基因技術有限公司
HUANG Shiang
Chairman

Hong Kong, November 9, 2021

As of the date of this announcement, the Board comprises Dr. Huang Shiang, Mr. Tu Zanbing and Ms. Chai Haijie as executive Directors, Mr. Huang Zuie-Chin, Mr. Peng Wei and Ms. Huang Lu as non-executive Directors, and Dr. Yao Shanglong, Dr. Xia Xinping and Mr. Gu Huaming as independent non-executive Directors.